SAN DIEGO, Nov. 06, 2017 (GLOBE NEWSWIRE) -- Obalon Therapeutics, Inc. (NASDAQ:OBLN), a vertically integrated medical technology company with the first and only FDA-approved swallowable, gas-filled intragastric balloon system for the treatment of obesity, today announced that Andy Rasdal, Chief Executive Officer, and Bill Plovanic, Chief Financial Officer of Obalon, will present at the following upcoming investor conferences:
Canaccord Genuity Medical Technologies & Diagnostics Forum
Thursday, November 9, 2017, Presentation at 2:30pm EST
Westin Grand Central Hotel
Webcast Available at: http://wsw.com/webcast/canaccord28/obln/
Stifel Healthcare Conference
Tuesday, November 14, 2017, Presentation at 8:45am EST
Lotte New York Palace Hotel
Webcast Available at: http://wsw.com/webcast/stifel10/obln/
Live audio webcasts of the presentation can be accessed through the links above. Replays of the webcasts will be available for 90 days following each presentation.
About Obalon Therapeutics, Inc.
Obalon Therapeutics, Inc. (NASDAQ:OBLN) is a San Diego-based company focused on developing and commercializing novel technologies for weight loss. The Obalon management team has over 150 combined years of experience in developing and commercializing novel medical technologies with a track record of financial and clinical excellence. For more information, please visit www.obalon.com.
For Obalon Therapeutics, Inc.
Investor Contact:
William Plovanic
Chief Financial Officer
Obalon Therapeutics, Inc.
Office: +1 760 607 5103
wplovanic@obalon.com
Media:
Megan Driscoll
EvolveMKD
Office Phone: +1 646 517 4220
mdriscoll@evolvemkd.com